J&J profits up amid drug gains
pharmafile | January 23, 2014 | News story | Sales and Marketing | FDA, J&J, JJ, Remicade, Zytiga, olysio, q4
Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous year.
The company posted $18.4 billion of sales in the three months to the end of the year – while worldwide sales for the whole of 2013 were also up, this time by 6.1%, on 2012 to $71.3 billion.
Pharma was the key driver in all this, with sales of $28.1 billion for the full-year 2013 representing an increase of 10.9% year-on-year: US sales were up 12.3% with international sales rising 9.6 per cent.
“Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our pharmaceutical business, the strength of key brands in our US OTC and other consumer businesses and continued progress in integrating Synthes into our medical devices and diagnostics business,” said J&J chief executive Alex Gorsky.
The group’s immunology franchise performed well, with Remicade (infliximab) sales for the year up 8.7% to $6.7 billion, while Simponi (golimumab) brought in $1.5 billion.
Oncology was also a strong area for J&J, with multiple myeloma treatment Velcade (bortezomib) and new prostate cancer drug Zytiga (abiraterone acetate) both making sales of $1.7 billion for the year.
Consumer sales of $14.7 billion in 2013 represented a slight increase of 1.7% on 2012, while medical devices and diagnostics revenue – including the acquisition of Synthes but net of the divestiture of DePuy – was $28.5 billion for the year, up 3.9 per cent.
The fourth quarter saw the FDA approve hepatitis C drug Olysio (simeprevir) and mantle cell lymphoma brand Imbruvica (ibrutinib), while Invokana (canagliflozin) for the treatment of adults with type 2 diabetes, was shown the green light in Europe.
On the corporate front J&J is also busy: earlier this month, it announced it has been offered $4.15 billion by private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics (OCD) business.
Adam Hill
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
